Xponance Inc. Acquires 25,543 Shares of Bristol-Myers Squibb (NYSE:BMY)

Xponance Inc. grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 8.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 317,381 shares of the biopharmaceutical company’s stock after acquiring an additional 25,543 shares during the quarter. Xponance Inc.’s holdings in Bristol-Myers Squibb were worth $13,181,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb during the first quarter worth $27,000. LGT Financial Advisors LLC raised its stake in Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares during the last quarter. Fairman Group LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $42,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth $47,000. Finally, Accent Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $46,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BMY shares. Barclays upped their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a research note on Thursday, August 22nd. Jefferies Financial Group lifted their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. TD Cowen lifted their price objective on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday, August 12th. Finally, BMO Capital Markets restated a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research note on Monday. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $55.00.

Bristol-Myers Squibb Stock Up 1.2 %

BMY stock opened at $50.02 on Tuesday. The company has a fifty day moving average of $47.88 and a 200-day moving average of $46.38. The stock has a market capitalization of $101.39 billion, a PE ratio of -16.13, a price-to-earnings-growth ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $59.28.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.43. The firm had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. Bristol-Myers Squibb’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.75 earnings per share. As a group, analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.80%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.